Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Blood

Volumn 126, Issue 1, 2015, Pages 61-68

  Liu, Ta Ming ^a   Woyach, Jennifer A ^a   Zhong, Yiming ^a   Lozanski, Arletta ^a   Lozanski, Gerard ^a   Dong, Shuai ^a   Strattan, Ethan ^a   Lehman, Amy ^b   Zhang, Xiaoli ^b   Jones, Jeffrey A ^a   Flynn, Joseph ^a   Andritsos, Leslie A ^a   Maddocks, Kami ^a   Jaglowski, Samantha M ^a   Blum, Kristie A ^a   Byrd, John C ^a   Dubovsky, Jason A ^a   Johnson, Amy J ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; CALCIUM; IBRUTINIB; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE B; PROTEIN KINASE LYN; PROTEIN KINASE SYK; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; LYN PROTEIN-TYROSINE KINASE; PHOSPHOLIPASE C GAMMA; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SIGNAL PEPTIDE;

ARTICLE; CALCIUM CELL LEVEL; CHRONIC LYMPHATIC LEUKEMIA; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; GENE MUTATION; IMMUNOBLOTTING; MISSENSE MUTATION; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHICKEN; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLS, CULTURED; CHICKENS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION, MISSENSE; PHOSPHOLIPASE C GAMMA; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84937841721     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-626846     Document Type: Article

References (30)

1. Gaidano G, Fòa R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012;122(10):3432-3438.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8): 804-815.
3. Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-574.
4. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: Revelations from the B-cell receptor. Blood. 2004;103(12):4389-4395.
5. Hallek M, Fischer K, Fingerle-Rowson G, et al; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
6. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4): 975-980.
7. Burger JA. Nurture versus nature: The microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:96-103.
8. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102(8):1515-1525.
9. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847.
10. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6): 1848-1854.
11. Packham G, Krysov S, Allen A, et al. The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: Proliferation or anergy. Haematologica. 2014;99(7):1138-1148.
12. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175-1184.
13. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014; 370(24):2286-2294.
14. Takata M, Kurosaki T. A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2. J Exp Med. 1996;184(1):31-40.
15. Reth M, Wienands J. Initiation and processing of signals from the B cell antigen receptor. Annu Rev Immunol. 1997;15:453-479.
16. Kurosaki T, Maeda A, Ishiai M, Hashimoto A, Inabe K, Takata M. Regulation of the phospholipase C-gamma2 pathway in B cells. Immunol Rev. 2000;176:19-29.
17. Wang D, Feng J, Wen R, et al. Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors. Immunity. 2000;13(1): 25-35.
18. Takata M, Sabe H, Hata A, et al. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca21 mobilization through distinct pathways. EMBO J. 1994;13(6):1341-1349.
19. Kurosaki T, Tsukada S. BLNK: Connecting Syk and Btk to calcium signals. Immunity. 2000; 12(1):1-5.
20. Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat Rev Immunol. 2010; 10(6):387-402.
21. Pleiman CM, Clark MR, Gauen LK, et al. Mapping of sites on the Src family protein tyrosine kinases p55blk, p59fyn, and p56lyn which interact with the effector molecules phospholipase C-gamma 2, microtubule-associated protein kinase, GTPaseactivating protein, and phosphatidylinositol 3-kinase. Mol Cell Biol. 1993;13(9):5877-5887.
22. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80-87.
23. Ombrello MJ, Remmers EF, Sun G, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med. 2012; 366(4):330-338.
24. Zhou Q, Lee GS, Brady J, et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cg2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet. 2012;91(4): 713-720.
25. Coelho V, Krysov S, Steele A, et al. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. Blood. 2013;122(15):2664-2672.
26. Watanabe D, Hashimoto S, Ishiai M, et al. Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling. J Biol Chem. 2001;276(42): 38595-38601.
27. Ozdener F, Dangelmaier C, Ashby B, Kunapuli SP, Daniel JL. Activation of phospholipase Cgamma2 by tyrosine phosphorylation. Mol Pharmacol. 2002;62(3):672-679.
28. Ishiai M, Kurosaki M, Pappu R, et al. BLNK required for coupling Syk to PLC gamma 2 and Rac1-JNK in B cells. Immunity. 1999;10(1): 117-125.
29. Falasca M, Logan SK, Lehto VP, Baccante G, Lemmon MA, Schlessinger J. Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO J. 1998;17(2):414-422.
30. Bae YS, Cantley LG, Chen CS, Kim SR, Kwon KS, Rhee SG. Activation of phospholipase C-gamma by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273(8): 4465-4469.